98
Participants
Start Date
October 21, 2020
Primary Completion Date
October 15, 2021
Study Completion Date
October 15, 2021
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
Standard of care
Participants will receive standard care starting on the day of enrollment for a total of 2 weeks. Standard of care treatment consist of an intravenous Remidesivir 200 mg loading dose and then 100 mg/daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg/daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients are discharged before 10 days, they are prescribed oral decadron 6 mg daily to complete the course of 10 days.
Rutgers New Jersey Medical School University Hospital, Newark
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
Rutgers, The State University of New Jersey
OTHER